在一項(xiàng)臨床試驗(yàn)中，患有分杈病變的患者使用Cordis心臟病學(xué)公司(Miami, FL, USA)的Cypher sirolimus釋放冠狀動(dòng)脈支架治療，在晚期面積喪失、再次接受治療和再次堵塞方面，療效顯著優(yōu)于Boston科學(xué)公司(Natick, MA, USA)的paclitaxel釋放Taxus支架。

這項(xiàng)包括205例患者的隨機(jī)對(duì)照臨床試驗(yàn)中發(fā)現(xiàn)，在6個(gè)月的時(shí)候，患有分杈病變的患者使用Cypher支架臂比Taxus支架臂出現(xiàn)再狹窄的可能性要低3倍。接受Cypher支架的患者在大血管和臨近側(cè)支血管晚期面積喪失等方面，效果較令人滿意。

這項(xiàng)研究結(jié)果在2005年11月Dallas(TX, USA)舉行的美國(guó)心臟學(xué)會(huì)年度科學(xué)會(huì)議上進(jìn)行了報(bào)道。這些發(fā)現(xiàn)得到了超過(guò)40項(xiàng)臨床試驗(yàn)項(xiàng)目的支持。
 
Sirolimus-Eluting Stent Bests Taxus Stent
 
Patients with bifurcation lesions fared significantly better in a clinical trial when treated with the Cypher sirolimus-eluting coronary stent of Cordis Cardiology (Miami, FL, USA) than with the paclitaxel-eluting Taxus stent of Boston Scientific (Natick, MA, USA) in areas of late loss, re-treatment, and re-blockage.

The 205-patient randomized, comparative trial found that at six months, patients with bifurcations in the Cypher stent arm were three times less likely to experience restenosis than patients in the Taxus stent arm of the study. The late loss results in the main vessel and adjoining side branch also favored those patients treated with the Cypher stent.

The study results were presented at the annual Scientific Sessions of the American Heart Association in November 2005 in Dallas (TX, USA). The findings are supported by a clinical trial program that included more than 40 studies.